Abstract Group: 11.1. Lung Cancer

Keyword 1: Lung cancer / Oncology Keyword 2: Thoracic oncology Keyword 3: Molecular pathology

Title: Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT

Dr. Ming 23627 Liu mingliu128@yahoo.com.cn MD 1, Dr. Lixia 23707 Zheng lixia-zheng@21cn.com 1, Dr. Chen 23708 He hecheen@163.com MD 1 and Prof. Dr Jun 23709 Xu xufeili@vip.163.com MD 1. 1 Guangzhou Institute of Respiratory Diseases, Guangzhou Medical College, Guangzhou, Guangdong, China, 510120.

Body: Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) therapy, but acquired resistance eventually develops at about 9-12 months. Overcoming the drug resistance is of great clinical and scientific significance. In this study, we showed that STAT3, ERK1/2 and AKT were persistently activated in the resistant cells with T790M mutation(PC9/ER) and 52 tumor samples from EGFR-TKIs resistant NSCLC patients. The growth inhibition of the triterpenoid compound cucurbitacin BE (Cu BE) was tested in vitro and in vivo against PC9/GR cells. Cu BE can inhibit the growth of PC9 and PC9/GR cells in a dose- and time-dependent manner, resulting in G2/M phase arrest and apoptosis. This was associated with inhibition of activated Stat3, ERK1/2 and AKT, increased level of autophagy (LC3B expression), and down-regulated the expression of caspase 3 and survivin. Moreover, in a nude mouse tumor xenograft model, Cu BE decreased the PC9/GR tumor volume by 46.4% (P < 0.05) compared with the mice treated with erlotinib. These data suggest that treatment with CuBE, which can inhibit the activation of STAT3, ERK1/2 and AKT, appears to be an effective strategy for NSCLC patients with EGFR-TKIs resistance.